摘要
目的:探讨替吉奥联合NP方案化疗对转移性乳腺癌患者癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)、恶性肿瘤特异性生长因子(TSGF)及黄体生成素(LH)、雌二醇(E2)水平的影响。方法:84例转移性乳腺癌患者,根据化疗方案均分为对照组和观察组,对照组患者采用NP标准方案化疗,观察组患者采用替吉奥联合NP方案化疗,4周为1周期、共2个周期;比较2组患者治疗前后生存质量测评量表(FACT-B)评分、血清CEA、CA125、CA153、TSGF、LH及E2的变化;治疗后随访半年、1年及2年,记录近期临床疗效、远期生存率及治疗期间的不良反应。结果:与治疗前比较,治疗后对照组FACT-B评分较治疗前降低(P<0.05),观察组FACT-B评分较治疗前升高(P<0.01);治疗后2组患者血清CEA、CA125、CA153、TSGF、LH及E2水平降低,观察组降低更明显(P<0.01);治疗后观察组总有效率(RR)为66.67%,显著高于对照组(35.71%),差异有统计学意义(P<0.01);观察组治疗后半年生存率与对照组比较差异无统计学意义(P>0.05),治疗后1年及2年生存率明显高于对照组(P<0.05或P<0.01),2组患者治疗期间均无严重不良反应发生。结论:替吉奥联合NP方案治疗转移性乳腺癌症近远期疗效优于单一NP方案治疗,可明显降低血清肿瘤标志分子及雌激素水平。
Objective： To investigate the effect of S-1 combined with routine chemotherapy on the level of tumor marker molecules（ CEA,CA125,CA153,TSGF,LH and E2） in the treatment of metastatic breast cancer patients. Methods： A total of 84 metastatic breast cancer patients were selected and divided into study group（ n = 42） and control group（ n = 42） according to the chemotherapy regimen. The control group was treated with NP standard chemotherapy regimen. The study group was treated with S-1 on the basis of the control group,4 weeks for 1 cycle,a total of 2 cycles of treatment.Comparing statistics before and after treatment of the adverse reactions,recent and long-term clinical efficacy of half a year,one year and two years of the 2 groups,the quality of life,serum changes of CEA,CA125,CA153,TSGF,LH and E2. Results： After treatment,the CEA,CA125,CA153,TSGF,LH and E2 levels in both groups were lower than before treatment,and the study group was lower than that of the control group（ P〈0. 01）. FACT-B scores of control group was lower after treatment（ P〈0. 05）,study group FACT-B scores increased（ P〈0. 01）. The total effective rate of the study group was 66. 67%,which was significantly higher than 35. 71% of the control group,differences were statistically significant（ P〈0. 01）. The 1-year and 2-year survival rates after treatment were significantly higher in the study group than in the control group（ P〈0. 05 or P〈0. 01）. No severe adverse reactions were found in both groups. Conclusion： S-1 combined with NP in the treatment of metastatic breast cancer has batter near and long-term effect,significantly reduce serum tumor marker molecules and estrogen levels.
作者
赵建昌
ZHAO Jianchang(Hematology and Oncology Department,People~ Hospital of Chongzhou,Chongzhou 611230,Sichuan,China)
出处
《贵州医科大学学报》
CAS
2018年第5期599-603,共5页
Journal of Guizhou Medical University
基金
四川省卫生厅基金项目(16PJ447)
关键词
乳腺肿瘤
肿瘤转移
替吉奥
肿瘤标志分子
雌激素
预后
breast cancer
tumor metastasis
teggio
tumor marker molecule
estrogen
prognosis
